BNB Plus secures $4.1 million in financing commitments

By AI, Created 9:02 PM UTC, May 26, 2026, /AGP/ – BNB Plus Corp. said Monday it has initial commitments for $4.1 million in convertible preferred stock financing and expects total proceeds to reach $5 million. The company plans to use the money to expand its digital asset treasury and support a strategic review that could reshape both its crypto and biotech businesses.

Why it matters: - BNB Plus is adding capital while it weighs strategic options for both its digital asset treasury business and its biotech subsidiary. - The company expects the financing to leave it with more than $16.4 million in cash and digital assets, based on values as of May 23, 2026. - The new funding is meant to give BNB Plus more flexibility as it reviews ways to maximize shareholder value.

What happened: - BNB Plus Corp. said it secured initial commitments for $4.1 million in convertible preferred stock financing. - The company expects additional commitments to lift total proceeds to $5 million. - The announcement came May 26, 2026, from New York. - Investors in the financing include Comstock Multichain Fund, managed by Silvermine Capital Advisors, and other new and existing digital-asset-native institutional investors, including Off the Chain, LP. - BNB Plus will enter an advisory arrangement with GlobalStake Infrastructure to lead the strategic review of the company’s business, assets and capital structure.

The details: - The financing includes two series of convertible preferred stock that are senior to common stock and convertible into common shares on a 1-for-1 basis. - The securities are backed by guarantees from the company’s digital asset treasury subsidiaries. - Series B-1 Preferred Stock, or prefunded B-1 purchase warrants, is priced at $1.05 per share. - The B-1 price reflects a 176% premium to the closing price of BNB Plus common stock on May 22, 2026. - Series B-1 carries an 8.0% annual dividend and a 1.5x liquidation preference. - B-1 shares will be issued to new investors and to existing investors who exercise certain outstanding warrants for cash. - Series B-2 Preferred Stock, or prefunded B-2 purchase warrants, is priced at $0.38 per share. - Series B-2 carries a 6.0% annual dividend and a 1.0x liquidation preference. - B-2 shares will be issued to existing investors who exchange common stock, warrant-related common stock and certain prefunded warrants. - Certain existing investors may also receive transferable rights to exchange common stock for Series B-2 Preferred Stock on a 1-for-1 basis for shares tied to existing warrants not otherwise exchanged. - For the first two years after closing, BNB Plus can satisfy preferred dividends by adding them to principal instead of paying cash. - Series B-1 investors will receive warrants covering 100% of the shares and/or prefunded warrants underlying their preferred investment. - Those warrants have a $0.76 exercise price and a three-year term. - BNB Plus said more details will be disclosed in a Current Report on Form 8-K filed with the SEC. - The financing is being done under an exemption from SEC registration requirements and related state securities laws. - The press release said the securities may not be offered or sold in the U.S. unless they are registered or exempt. - BNB Plus said the financing is not an offer to sell or a solicitation to buy in any jurisdiction where that would be unlawful.

Between the lines: - The company is pairing a capital raise with a broader review that could lead to asset sales, partnerships, licensing deals or other transactions at LineaRx. - BNB Plus said its LineaRx subsidiary, which provides therapeutic DNA production services, recently reached profitability in Q2 FY2026. - GlobalStake chairman Richard Shorten, who will lead the review, brings more than 30 years of experience in institutional finance, corporate law and emerging technology. - Shorten has served on multiple public company boards and has worked as a turnaround operator in telecom, media and digital assets. - The financing structure suggests BNB Plus is trying to preserve near-term liquidity while it evaluates longer-term strategic alternatives. - The company is also operating in a volatile corner of the market, where digital asset prices and Nasdaq listing compliance remain key risks.

What’s next: - BNB Plus said it will file a Current Report on Form 8-K with additional transaction terms. - GlobalStake will lead the strategic review of the business, assets and capital structure. - The review will focus on two main paths: digital asset and AI infrastructure opportunities, and monetization options for LineaRx. - The company said possible outcomes for LineaRx could include partnerships, licensing arrangements, asset sales or other transactions. - BNB Plus also said it continues to commercialize its nucleic acid production solutions for the biopharmaceutical and diagnostics markets.

The bottom line: - BNB Plus is buying time and capital to decide whether its future value lies in digital assets, biotech, or a mix of both.